ADIAL PHARMACEUTICALS, INC.
ADILDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AD04 (ondansetron) | Phase 3 | Alcohol Use Disorder | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ADIAL PHARMACEUTICALS, INC.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in ADIAL PHARMACEUTICALS, INC.'s (ADIL) pipeline across Phase 3. Its lead program is AD04 (ondansetron) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ADIAL PHARMACEUTICALS, INC.'s next FDA catalyst?→
ADIAL PHARMACEUTICALS, INC.'s (ADIL) next tracked catalyst is a Earnings expected November 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ADIL biotech catalysts?→
Add ADIL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ADIAL PHARMACEUTICALS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.